文献速递脑血管病

P2Y12抑制剂联合阿司匹林与单用阿司匹林在轻型卒中或高危TIA患者中的比较

P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack.
PubMed 文献 · Stroke · 2021-05-27

结果显示双联治疗在症状发作24小时内启动可降低24%的卒中复发风险,但增加重度或中度出血风险,且该出血风险主要见于治疗超过21天或使用替格瑞洛的试验。

要点

  • 双联抗血小板治疗降低轻型卒中或高危TIA患者卒中复发风险。
  • 双联治疗不改变全因死亡、心血管死亡、轻度出血或心肌梗死风险。
  • 双联治疗增加重度或中度出血风险,尤其治疗超过21天或使用替格瑞洛时。

核心结论

  • 在非心源性轻型卒中或高危TIA患者中,阿司匹林联合氯吡格雷/替格瑞洛的双联治疗比阿司匹林单药更有效预防卒中复发,但重度或中度出血风险有小幅绝对增加。

研究设计与样本

  • 系统评价与荟萃分析,检索Medline、Embase、Cochrane对照试验中心注册库和Cochrane图书馆2012年1月至2020年7月的随机对照试验。
  • 采用DerSimonian-Laird随机效应模型估计汇总风险比(RR)及95%CI,用Cochran Q统计量和I2检验评估异质性。

主要发现

  • 症状发作24小时内启动双联治疗使卒中复发风险降低24%(RR 0.76,95%CI 0.68-0.83,I2=0%)。
  • 双联治疗与全因死亡(RR 1.30,95%CI 0.90-1.89,I2=0%)、心血管死亡(RR 1.34,95%CI 0.56-3.17,I2=0%)、轻度出血(RR 1.25,95%CI 0.37-4.29,I2=94%)或心肌梗死(RR 1.45,95%CI 0.62-3.39,I2=0%)风险改变无关。
  • 双联治疗与重度或中度出血风险增加相关(RR 2.17,95%CI 1.16-4.08,I2=41%);敏感性分析显示该关联仅限于治疗持续时间超过21天的试验(RR 2.86,95%CI 1.75-4.67,I2=0%)或使用替格瑞洛的试验(RR 2.17,95%CI 1.16-4.08,I2=37%),而在21天内或使用氯吡格雷时未见此关联。

关键数值与推荐

  • 卒中复发风险降低24%(RR 0.76,95%CI 0.68-0.83,I2=0%)。
  • 重度或中度出血风险增加(RR 2.17,95%CI 1.16-4.08,I2=41%)。
  • 治疗超过21天时重度或中度出血风险增加(RR 2.86,95%CI 1.75-4.67,I2=0%)。

临床怎么用

  • 对非心源性轻型卒中或高危TIA患者,可考虑在症状发作24小时内启动阿司匹林联合氯吡格雷/替格瑞洛的双联抗血小板治疗以预防卒中复发。
  • 应权衡出血风险,尤其对于治疗持续时间超过21天或使用替格瑞洛的患者需警惕重度或中度出血。

局限性

  • 纳入试验数量有限(4项),可能影响结果的稳健性。
  • 轻度出血分析异质性高(I2=94%)。
  • 重度或中度出血风险的敏感性分析提示关联受治疗持续时间和药物种类影响,但需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: We performed a systemic review and meta-analysis to elucidate the effectiveness and safety of dual antiplatelet (DAPT) therapy with P2Y12 inhibitors (clopidogrel/ticagrelor) and aspirin versus aspirin monotherapy in patients with mild ischemic stroke or high-risk transient ischemic attack. METHODS: Following Preferred Reported Items for Systematic Review and Meta-Analysis standards for meta-analyses, Medline, Embase, Cochrane Central Register of Controlled Trials, and the Cochrane Library were searched for randomized controlled trials that included patients with a diagnosis of an acute mild ischemic stroke or high-risk transient ischemic attack, intervention of DAPT therapy with clopidogrel/ticagrelor and aspirin versus aspirin alone from January 2012 to July 2020. The outcomes included subsequent stroke, all-cause mortality, cardiovascular death, hemorrhage (mild, moderate, or severe), and myocardial infarction. A DerSimonian-Laird random-effects model was used to estimate pooled risk ratio (RR) and corresponding 95% CI in R package meta. We assessed the heterogeneity of data across studies with use of the Cochran Q statistic and I2 test. RESULTS: Four eligible trials involving 21 493 participants were included in the meta-analysis. DAPT therapy started within 24 hours of symptom onset reduced the risk of stroke recurrence by 24% (RR, 0.76 [95% CI, 0.68-0.83], I2=0%) but was not associated with a change in all-cause mortality (RR, 1.30 [95% CI, 0.90-1.89], I2=0%), cardiovascular death (RR, 1.34 [95% CI, 0.56-3.17], I2=0%), mild bleeding (RR, 1.25 [95% CI, 0.37-4.29], I2=94%), or myocardial infarction (RR, 1.45 [95% CI, 0.62-3.39], I2=0%). However, DAPT was associated with an increased risk of severe or moderate bleeding (RR, 2.17 [95% CI, 1.16-4.08], I2=41%); further sensitivity tests found that the association was limited to trials with DAPT treatment duration over 21 days (RR, 2.86 [95% CI, 1.75-4.67], I2=0%) or ticagrelor (RR, 2.17 [95% CI, 1.16-4.08], I2=37%) but not within 21 days or clopidogrel. CONCLUSIONS: In patients with noncardioembolic mild stroke or high-risk transient ischemic attack, DAPT with aspirin and clopidogrel/ticagrelor is more effective than aspirin alone for recurrent stroke prevention with a small absolute increase in the risk of severe or moderate bleeding.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Li ZX, Xiong Y, Gu HQ, et al. P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack. Stroke. 2021. PMID: 34039032. doi:10.1161/STROKEAHA.120.033040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。